150 related articles for article (PubMed ID: 12481382)
21. [The new quinolones].
Lontie M
J Pharm Belg; 1989; 44(4):292-301. PubMed ID: 2691640
[TBL] [Abstract][Full Text] [Related]
22. In-vitro activity of quinolones against different species of staphylococci of recent clinical isolation.
Rabagliati AM; Fiorio P; Cavallo R; Mills V; Penna R
J Chemother; 1991 Jan; 3 Suppl 1():176-8. PubMed ID: 12041759
[TBL] [Abstract][Full Text] [Related]
23. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
24. [Synthesis and antibacterial activity of 5-amino-6, 8-difluoro-1-(5-fluoro-2-pyridyl)-7-(3-methyl-1-piperazinyl)-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and its analogues].
Liu JY; Wei YG; Guo HY
Yao Xue Xue Bao; 2001 Jun; 36(6):419-22. PubMed ID: 12585124
[TBL] [Abstract][Full Text] [Related]
25. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
26. In vitro antibacterial and antimalarial activity of dehydrophenylalanine-containing undecapeptides alone and in combination with drugs.
Sharma SP; Sharma J; Kanwar SS; Chauhan VS
Int J Antimicrob Agents; 2012 Feb; 39(2):146-52. PubMed ID: 22118799
[TBL] [Abstract][Full Text] [Related]
27. Norfloxacin decreases bacterial adherence of quinolone-resistant strains of Escherichia coli isolated from patients with cirrhosis.
Gascón I; Pascual S; Plazas J; Sánchez J; Francés R; Más P; Zapater P; Pérez-Mateo M; Such J
Aliment Pharmacol Ther; 2005 Mar; 21(6):701-7. PubMed ID: 15771756
[TBL] [Abstract][Full Text] [Related]
28. The influence of the SOS response on the activity of 4-quinolones and zidovudine against some strains of Enterobacteria.
Mascellino MT; Farinelli S; Iegri F; Iona E
New Microbiol; 1998 Jan; 21(1):31-40. PubMed ID: 9497927
[TBL] [Abstract][Full Text] [Related]
29. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone.
Dal SM; Bovio C; Culici M; Braga PC
Drugs Exp Clin Res; 2002; 28(2-3):75-82. PubMed ID: 12224380
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
31. Investigation of antimicrobial activities of indole-3-aldehyde hydrazide/hydrazone derivatives.
Gurkok G; Altanlar N; Suzen S
Chemotherapy; 2009; 55(1):15-9. PubMed ID: 18974644
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal action of PD127,391, an enhanced spectrum quinolone.
Lewin CS; Amyes SG
J Med Microbiol; 1990 Sep; 33(1):67-70. PubMed ID: 2231674
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
[TBL] [Abstract][Full Text] [Related]
34. [Mutations of gyrA in ciprofloxacin resistant Escherichia coli strains].
Eraç B; Gill A; Amyes SG; Gülay Z
Mikrobiyol Bul; 2003; 37(2-3):125-30. PubMed ID: 14593893
[TBL] [Abstract][Full Text] [Related]
35. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay.
Zeiler HJ; Petersen U; Gau W; Ploschke HJ
Arzneimittelforschung; 1987 Feb; 37(2):131-4. PubMed ID: 3555512
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain.
Gobernado M; Valdés L; Alós JI; García-Rey C; Dal-Ré R; García-de-Lomas J;
Rev Esp Quimioter; 2007 Mar; 20(1):68-76. PubMed ID: 17530038
[TBL] [Abstract][Full Text] [Related]
37. The physicochemical and antibacterial properties of ciprofloxacin-Mg2+ complex.
Adepoju-Bello AA; Coker HA; Eboka CJ; Abioye AO; Ayoola GA
Nig Q J Hosp Med; 2008; 18(3):133-6. PubMed ID: 19062475
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.
Giacometti A; Cirioni O; Kamysz W; D'Amato G; Silvestri C; Licci A; Nadolski P; Riva A; Lukasiak J; Scalise G
Int J Antimicrob Agents; 2005 Sep; 26(3):235-40. PubMed ID: 16122911
[TBL] [Abstract][Full Text] [Related]
39. Effect of chloroquine on the bioavailability of ciprofloxacin in humans.
Ilo CE; Ilondu NA; Okwoli N; Brown SA; Elo-Ilo JC; Agbasi PU; Orisakwe OE
Am J Ther; 2006; 13(5):432-5. PubMed ID: 16988539
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial activity of Substance P and Neuropeptide Y against laboratory strains of bacteria and oral microorganisms.
Hansen CJ; Burnell KK; Brogden KA
J Neuroimmunol; 2006 Aug; 177(1-2):215-8. PubMed ID: 16808979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
